Osteochondritis
Methodology & AI Transparency ⓘ
Osteochondritis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Osteochondritis (ICD-10-CM M93.90), Osteoarthritis, Gout & Joint Pain protocols prioritize synovial fluid crystal/cell in Osteochondritis (M93.90: analysis when effused) paired with baseline and interval hs-CRP & Erythrocyte in Osteochondritis (M93.90: Sedimentation Rate) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code M93.90 categorizes Osteochondritis under Osteoarthritis, Gout & Joint Pain.
- 3 Typical cash cost range: Clinicians assessing Osteochondritis focus on low-grade synovial metalloproteinase in Osteochondritis (M93.90: release) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Osteochondritis: maintaining hs-CRP & Erythrocyte in Osteochondritis (M93.90: Sedimentation Rate) within hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M93.90).
Ask our AI Specialists anything about Osteochondritis
What Is Osteochondritis?
For patients presenting with Osteochondritis (ICD-10-CM M93.90), Osteoarthritis, Gout & Joint Pain protocols prioritize synovial fluid crystal/cell in Osteochondritis (M93.90: analysis when effused) paired with baseline and interval hs-CRP & Erythrocyte in Osteochondritis (M93.90: Sedimentation Rate) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Osteochondritis (M93.90) features low-grade synovial metalloproteinase in Osteochondritis (M93.90: release). therapeutic stabilization in arthritis & joints is verified against Weight-Bearing Joint Radiograph [Osteochondritis M93.90].
Common Symptoms & Clinical Signs
- • Presentation of Osteochondritis (M93.90): activity-related deep aching in Osteochondritis (M93.90: joint pain in)
- • Secondary Osteochondritis clinical sign: brief morning joint in Osteochondritis (M93.90: stiffness)
- • Symptom flares in Osteochondritis correlating with hs-CRP & Erythrocyte in Osteochondritis (M93.90: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M93.90)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Osteochondritis (M93.90: analysis when effused) evaluation (M93.90)
Osteochondritis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M93.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Osteochondritis (M93.90: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M93.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Osteochondritis M93.90] | Preserved joint-space width (M93.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Osteochondritis (M93.90: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M93.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Osteochondritis
Treatment selection for Osteochondritis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Osteochondritis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of HLX01 in patients with moderate-to-severe autoimmune joint HLX01 plus methotrexate improved clinical outcomes compared with placebo in Chinese patients with autoimmune joint pain (autoimmune joint pain (rheumatoid arthritis)) who had inadequate responses to methotrexate. Arthritis research & therapy • 2022-06-10 • Phase III Randomized Trial | N = 183 | 88/100 | PMID 35689239 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of baricitinib in patients with moderate-to-severe autoimmune joint pain Treatment with baricitinib 4 mg demonstrated efficacy for up to 3 years and was well tolerated. Rheumatology (Oxford, England) • 2021-05-14 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33200220 ↗ |
| What the Latest Evidence Really Says About Association between statin use and incidence or progression of wear-and-tear Statin use may not be associated with a lower risk of incidence and progression of OA, regardless of joint site. Osteoarthritis and cartilage • 2020-09-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 32360737 ↗ |
| Can This Approach Help? Inside the Latest Research on Exploratory analysis of the potential disconnect between objective inflammatory There is a potential disconnect between objective measures of inflammation and clinical outcome responses in patients with axSpA. RMD open • 2024-08-28 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39209369 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical experience and safety of Janus kinase inhibitors in giant cell We present encouraging observational data on JAKi in GCA in one of the hitherto largest case series with long-term follow-up. Frontiers in immunology • 2023-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37304255 ↗ |
Osteochondritis Patient Community & “People Like Me” Threads
Filter Osteochondritis community threads and patient logs by age, biological sex, dosage, and treatment duration.